All In Biotech

Investigational drug · Phase 3

IBI112

Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Psoriasis.

Phase 3

Last checked: Nov 19, 2026Latest source record: Dec 22, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

2

1 still active

All registered trials

7

Any phase or sponsor naming "IBI112"

First trial start

2023

Oct 10, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "IBI112", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Psoriasis

Approved drugs for the same conditions: Immunology and inflammation

Largest trials

Live from ClinicalTrials.gov: studies naming "IBI112" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 2 on PubMed

Also in development for Psoriasis

  • HSK44459Phase 39 trials

    Haisco Pharmaceutical Group Co., Ltd. · Psoriasis, Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis

  • TQH3906Phase 34 trials

    Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Psoriasis, Systemic Lupus Erythematosus, Psoriatic Arthritis

  • AK111Phase 32 trials

    Akeso · Psoriasis, Skin Diseases, Ankylosing Spondylitis

  • Alumis Inc · Plaque Psoriasis, Psoriasis (PsO), Psoriasis

  • CMAB015Phase 31 trial

    Taizhou Mabtech Pharmaceutical Co.,Ltd · Psoriasis

  • HPP737Phase 31 trial

    Newsoara Biopharma Co., Ltd. · Psoriasis

  • LZM012Phase 31 trial

    Livzon Pharmaceutical Group Inc. · Psoriasis

  • Alumis Inc · Plaque Psoriasis, Psoriasis (PsO), Psoriasis

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.